Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
10 juil. 2018 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the “’Company’) Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics Non-Dilutive Funding...
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
11 juin 2018 07h00 HE
|
Summit Therapeutics plc
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018
31 mai 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance
11 mai 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Accelerate Diagnostics reports Q1 2018 financial results
09 mai 2018 16h03 HE
|
Accelerate Diagnostics, Inc.
TUCSON, Ariz., May 09, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up...
Melinta Therapeutics Reports First Quarter 2018 Financial Results
08 mai 2018 16h01 HE
|
Melinta Therapeutics
Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X...
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
08 mai 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
07 mai 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
23 avr. 2018 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic...
Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
13 mars 2018 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 13, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the discovery of a series of antibiotic compounds that kill...